- Home
- SWK vs JAZZ Comparison
SWK vs JAZZ Comparison
Compare SWK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWK | JAZZ |
|---|---|---|
| Founded | 1843 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.8B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | SWK | JAZZ |
|---|---|---|
| Price | $78.51 | $169.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $91.63 | ★ $201.80 |
| AVG Volume (30 Days) | ★ 1.6M | 984.7K |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.90 | N/A |
| Revenue | ★ $15,166,300,000.00 | $4,157,832,999.00 |
| Revenue This Year | $0.05 | $6.00 |
| Revenue Next Year | $2.96 | $6.47 |
| P/E Ratio | $27.88 | ★ N/A |
| Revenue Growth | N/A | ★ 4.14 |
| 52 Week Low | $53.91 | $95.49 |
| 52 Week High | $91.06 | $182.99 |
Technical Indicators
Market Signals| Indicator | SWK | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 53.48 |
| Support Level | $74.16 | $162.60 |
| Resistance Level | $75.69 | $175.80 |
| Average True Range (ATR) | 2.18 | 4.08 |
| MACD | 0.35 | -0.62 |
| Stochastic Oscillator | 71.35 | 51.59 |
Price Performance
Historical ComparisonAbout SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.